22:43 , Jul 7, 2017 |  BioCentury  |  Finance

Generalists needed

Following a nearly two-year political overhang on the biotech sector, buysiders believe sentiment once again may be turning positive and starting to catch up with the industry’s positive fundamentals. As evidence, they point to the continued...
19:00 , Jun 30, 2017 |  BC Week In Review  |  Clinical News

FDA approves Adamis' Symjepi epinephrine pre-filled syringe

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) said FDA approved an NDA for Symjepi epinephrine for the emergency treatment of allergic reactions including anaphylaxis. Symjepi is a pre-filled syringe containing a single dose of 0.3 mg epinephrine. Adamis...
18:10 , Apr 28, 2017 |  BC Week In Review  |  Financial News

Adamis completes follow-on

Respiratory disease and allergy company Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) raised $17.3 million in a follow-on through the sale of 4.9 million shares at $3.50 underwritten by Raymond James and the Maxim Group. The figures include...
02:02 , Jan 24, 2017 |  BC Week In Review  |  Clinical News

Epinephrine pre-filled single dose syringe regulatory update

Adamis said FDA accepted for review a resubmitted NDA for epinephrine pre-filled single dose syringe for the emergency treatment of anaphylaxis. The company expects an FDA decision within 6 months of the resubmission date of...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Financial News

Adamis completes direct public offering

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP), San Diego, Calif.   Business: Inflammation, Cancer, Endocrine/Metabolic   Date completed: 2016-07-29   Type: Direct public offering   Raised: $11.1 million   Units: 3.6 million   Price: 3.10 (unit)   Shares after offering: 20.9 million   Placement agent: Maxim...
07:00 , Jul 18, 2016 |  BC Week In Review  |  Financial News

Adamis completes private placement of units

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP), San Diego, Calif.   Business: Inflammation, Cancer, Endocrine/Metabolic   Date completed: 2016-07-12   Type: Private placement of units   Raised: $5 million   Units: 1.7 million   Price: $2.90 (unit)   Shares outstanding prior: 15.1 million   Investor: Institutional...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Epinephrine pre-filled single dose syringe regulatory update

FDA issued a complete response letter to Adamis for its epinephrine pre-filled single dose syringe for emergency treatment of anaphylaxis. According to Adamis, FDA said the company must expand its human factors and reliability studies...
08:00 , Feb 1, 2016 |  BC Week In Review  |  Financial News

Adamis completes private placement of convertible preferred units

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP), San Diego, Calif.   Business: Infectious, Inflammation   Date completed: 2016-01-26   Type: Private placement of convertible preferred units   Raised: $5 million   Shares: 1.2 million   Price: $4.23 (unit)   Shares outstanding prior: 13.4 million   Investor:...
08:00 , Jan 25, 2016 |  BC Week In Review  |  Clinical News

Epinephrine pre-filled single dose syringe regulatory update

FDA accepted for review an NDA for epinephrine pre-filled syringe from Adamis for the emergency treatment of anaphylaxis. The PDUFA date is June 4. Last March, FDA issued a complete response letter for the product...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Financial News

Adamis financial update

Adamis Pharmaceuticals Corp. (NASDAQ:ADMP), San Diego, Calif.   Business: Infectious, Inflammation   Date announced:2014-06-23   Note: Adamis filed a shelf registration covering the sale of up to $50 million of its securities. The company, which closed Friday at...